Your browser doesn't support javascript.
loading
Elevated interleukin 8 and matrix metalloproteinase 9 levels are associated with myocardial pathology in users of anabolic-androgenic steroids.
Gregersen, Ida; Scarth, Morgan Elizabeth; Abdullah, Rang; Thorsby, Per Medbøe; Hauger, Lisa E; Haugaa, Kristina H; Sagen, Ellen Lund; Michelsen, Annika E; Ueland, Thor; Edvardsen, Thor; Aukrust, Pål; Almaas, Vibeke Marie; Bjørnebekk, Astrid Kristine; Halvorsen, Bente.
Affiliation
  • Gregersen I; Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Sognsvannsveien 20, 0372 Oslo, Norway.
  • Scarth ME; Anabolic Androgenic Steroid Research Group, Section of Clinical Addiction Research, Division of Mental Health and Addiction, Oslo University Hospital, Sognsvannsveien 21, 0372 Oslo, Norway.
  • Abdullah R; Anabolic Androgenic Steroid Research Group, Section of Clinical Addiction Research, Division of Mental Health and Addiction, Oslo University Hospital, Sognsvannsveien 21, 0372 Oslo, Norway.
  • Thorsby PM; ProCardio Center for Research-Based Innovation, Department of Cardiology, Oslo University Hospital, Rikshospitalet, Sognsvannsveien 20, 0372 Oslo, Norway.
  • Hauger LE; Institute of Clinical Medicine, University of Oslo, Kirkeveien 166, 0450, Oslo, Norway.
  • Haugaa KH; Institute of Clinical Medicine, University of Oslo, Kirkeveien 166, 0450, Oslo, Norway.
  • Sagen EL; Hormone Laboratory, Department of Medical Biochemistry, Oslo University Hospital, Aker, Trondheimsveien 235,0586 Oslo, Norway.
  • Michelsen AE; Biochemical Endocrinology and Metabolism Research Group, Oslo University Hospital, Aker, Trondheimsveien 235, 0586 Oslo, Norway.
  • Ueland T; Anabolic Androgenic Steroid Research Group, Section of Clinical Addiction Research, Division of Mental Health and Addiction, Oslo University Hospital, Sognsvannsveien 21, 0372 Oslo, Norway.
  • Edvardsen T; National Centre for Epilepsy, Section of Clinical Psychology and Neuropsychology, Oslo University Hospital, Henriksens vei, Sandvika, Norway.
  • Aukrust P; ProCardio Center for Research-Based Innovation, Department of Cardiology, Oslo University Hospital, Rikshospitalet, Sognsvannsveien 20, 0372 Oslo, Norway.
  • Almaas VM; Institute of Clinical Medicine, University of Oslo, Kirkeveien 166, 0450, Oslo, Norway.
  • Bjørnebekk AK; Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Sognsvannsveien 20, 0372 Oslo, Norway.
  • Halvorsen B; Institute of Clinical Medicine, University of Oslo, Kirkeveien 166, 0450, Oslo, Norway.
Eur J Prev Cardiol ; 31(12): 1469-1476, 2024 Sep 06.
Article in En | MEDLINE | ID: mdl-38573232
ABSTRACT

AIMS:

In the current paper, we aim to explore the effect of both current and former long-term anabolic-androgenic steroid (AAS) use on regulation of systemic inflammatory markers and mediators of extracellular matrix (ECM) remodelling and their association with hormones and echocardiographic myocardial pathology in weightlifters. METHODS AND

RESULTS:

In a cross-sectional study, 93 weightlifting AAS users, of whom 62 were current and 31 were past users, with at least 1-year cumulative AAS use (mean 11 ± 7 accumulated years of AAS use), were compared with 54 non-using weightlifting controls (WLCs) using clinical interview, blood pressure measurements, and echocardiography. Serum levels of interleukin (IL)-6, IL-8, tumour necrosis factor (TNF), interferon (IFN)-γ, growth differentiation factor (GDF)-15, and matrix metalloproteinase (MMP)-9, sex hormones, and lipids were analysed. It was found that serum levels of IL-8, GDF-15, and MMP-9 were significantly increased in current AAS users compared with former users and WLCs. Matrix metalloproteinase 9, but not IL-8, correlated consistently with sex hormone levels, and sex hormone levels correlated consistently with mean wall thickness, in current users. Moreover, HDL cholesterol was significantly lower in current vs. former AAS users and significantly inversely correlated with MMP-9 in current users. Further, in current users, MMP-9 and IL-8 correlated with markers of myocardial strain, and MMP-9 also correlated with indices of cardiac mass, which was not seen in former users. Mediation analyses suggested that MMP-9 could partly explain hormone-induced alterations in markers of myocardial damage in current users.

CONCLUSION:

Long-term AAS is associated with increased levels of markers of inflammation and ECM remodelling, which seems to have a hormone-dependent (MMP-9) and a hormone-independent (IL-8) association with markers of myocardial dysfunction.
Long-term use of anabolic-androgenic steroids (AASs) can increase inflammation and mediators of extracellular matrix (ECM) remodeling, which potentially could be involved in myocardial pathology seen in individuals using such steroids.Anabolic-androgenic steroid use increased levels of inflammatory marker IL-8 and marker of ECM remodelling matrix metalloproteinase-9 (MMP-9).Interleukin-8 and MMP-9 were both associated with myocardial pathology in current, but not former, users, suggesting that these markers are associated with the risk of myocardial damage during AAS use.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers / Interleukin-8 / Matrix Metalloproteinase 9 Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Eur J Prev Cardiol Year: 2024 Type: Article Affiliation country: Norway

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers / Interleukin-8 / Matrix Metalloproteinase 9 Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Eur J Prev Cardiol Year: 2024 Type: Article Affiliation country: Norway